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B
oth the AABB’s Guidelines for Prenatal and Peri-
natal Immunohematology1 and the practice
bulletin of the American College of Obstetri-
cians and Gynecologists (ACOG) on “Manage-
ment of Alloimmunization during Pregnancy”2 advocate
testing pregnant women for unexpected antibodies to red
blood cell (RBC) antigens at the first-trimester visit. This
testing serves to detect those alloantibodies capable of
causing hemolytic disease of the fetus and newborn
(HDFN). If no antibodies are detected at the initial visit, no
additional testing is advocated later in pregnancy, except
before administering Rh immune globulin (RhIG) prophy-
laxis, when there is a history of potentially significant anti-
bodies or blood transfusions, or if blood transfusions are
necessary.
However, testing for unexpected antibodies before
administering RhIG prophylaxis (to prevent anti-D
alloimmunization) was once mandated by wording in
product circulars for RhIG distributed by Ortho Diagnos-
tics between 1968 and 1981.3 The statement under the
subheading “Indications” read “The mother must not
already be alloimmunized to the Rho(D) factor.” This
requirement was dropped once routine antenatal prophy-
laxis at 28 to 30 weeks’ gestation was introduced,4 first in
Canada in 1977 and shortly thereafter in the United
States,5,6 because the antenatally administered RhIG
anti-D can be detected at delivery, and RhIG cannot be
differentiated from immune anti-D.7,8
Currently, no accrediting agency in the United States
mandates testing before RhIG administration, although a
recommendation for testing may be inferred from AABB
Standard 5.20.2:9 “Women who are pregnant or who have
been pregnant recently shall be considered for Rh
Immune Globulin administration when: 3) The woman is
not known to be actively immunized to the D antigen.”
When testing for unexpected antibodies after the
woman has received RhIG earlier in pregnancy, a
minipanel of three reagent D– RBC samples that between
them carry all of the FDA-required antigens for antibody
detection except the D antigen (i.e., r′r, r″r, and rr RBCs)
can be constituted from reagent RBC panels used in anti-
body identification studies.10 If used in conjunction with
either a two- (R1R1, R2R2) or a three- (R1R1, R2R2, rr) reagent
RBC sample screening set, the passively acquired anti-D
can be identified in many cases and the presence of non-D
antibodies excluded.
A number of investigators have shown that testing D+
pregnant women for unexpected antibodies to RBC anti-
gens beyond that described above is rarely clinically
helpful.11-15 However, in this issue of TRANSFUSION,
Dajak and colleagues16 report cases of D and non-D anti-
bodies that were not detected at the first-trimester testing
yet caused “significant” HDFN. Their data are from
Croatia, where it is customary to perform additional tests
for unexpected antibodies on D– pregnant women at 28
and 34 weeks’ gestation, and D+ women at 34 weeks’ ges-
tation. The study involved 84,000 pregnant women
encountered over a 15-year period. Unexpected antibod-
ies to RBC antigens were seen in 1105 (1.32%). Anti-D was
seen in 1.3% of D– women (n = 15,200), and the incidence
of non-D antibodies was 0.2%.
Of concern were 87 pregnancies in which antibody
screening tests were nonreactive at the first-trimester
visit, but were reactive either during the third trimester or
at delivery. Seventy-two such pregnancies involved anti-D,
14 of which were detected by screening at Week 28, 22 at
Week 34, and 31 at delivery. Anti-D was seen at delivery
in five cases in which no testing had been done during
pregnancy.
There were 19 cases of HDFN resulting from antibod-
ies that were not detected during the first trimester. Of
these, 12 resulted in HDFN requiring exchange transfu-
sion after delivery; the antibodies involved were D(5), c(6),
and E(1). There were six cases treated with simple trans-
fusion (three due to anti-D and one example each due to
anti-c, anti-C, and anti-Ce). The authors also encountered
the remarkable case of fetal death at 36 weeks’ gestation
due to anti-Rh17. The mother had been transfused at 21
weeks’ gestation when tests for unexpected antibodies
and crossmatches were nonreactive.
There were no cases in which the first-trimester
testing missed non-Rh antibodies that caused intrauter-
ine death or HDFN requiring treatment at delivery.
However, there were three pregnancies with detectable
antibodies at the first-trimester visit, all involving anti-K
with a K+ fetus; one of these resulted in intrauterine death.
No other non-Rh antibodies were implicated in HDFN.
The data of Dajak and colleagues16 are in accord with
other published reports11-14 on the rate of alloimmuniza-
tion among D+ women during pregnancy. The figures for
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1366 TRANSFUSION Volume 51, July 2011
four studies were 20 in 13,143 in Adeniji and colleagues,11
6 in 9348 in Rothenberg and colleagues,12 42 in 17,568 in
Heddle and colleagues, and 13 in 3012 in Andersen and
colleagues.14 The overall incidence was 0.18%, substanti-
ating the findings of Dajak and colleagues16 and is further
supported by the report of Bowell and colleagues15 on
70,000 pregnancies in which the incidence of late-onset
alloimmunization, including anti-D, was 0.38%. Apart
from the anti-Rh17 case described, none of the antibodies
caused fetal demise or HDFN that required medical inter-
vention before delivery.
It should be noted that it is not current practice in
Croatia or many other countries to provide D– women
with antenatal RhIG prophylaxis at 26 to 28 weeks’ gesta-
tion, as is the recommended standard of care in North
America. Indeed, according to the results of a 2003 inter-
national survey, antenatal RhIG prophylaxis is practiced
nationally in only two other countries (United Kingdom
and the Netherlands), and in Spain, Poland, and Austria it
is practiced in parts of the country.17
Also, the authors use the term “severe HDFN” in the
title and throughout the article, which they define as
HDFN requiring simple or exchange transfusion or HDFN
resulting in fetal or infant death. Others, especially those
from countries with the resources to monitor and treat
fetal hemolytic disease in utero,18 might apply “severe”
only to the latter.
Two other articles on alloimmunization are relevant
to this discussion. Koelewijn and colleagues19 studied the
risk factors associated with alloimmunization during
pregnancy among D+ women. They concluded that trans-
fusion is by far the most important independent risk
factor, followed by parity, major surgery, and hematologic
disease. They present a flow diagram for a screening
program based on preselection of women with clinical risk
factors; no antibody detection tests are required in the
absence of risk factors.
In a 1986 article, Howard and coworkers7 noted that
while anti-D accounted for the greatest fetal mortality
and morbidity, anti-c caused the second most morbidity.
They state that the production of non-D antibodies could
be avoided by preselecting RBCs when transfusing pre-
menopausal women. Koelewijn and coworkers17 sug-
gested matching for both K and c antigens. Blumberg20
discussed the issue of antigen matching RBC units for
patients other the chronically transfused. He was not
persuaded that matching beyond ABO and D is clinically
indicated for patients other than the chronically trans-
fused and premenopausal women, but additional match-
ing for the latter has not been widely adopted and is not
mentioned in either the AABB or British Committee for
Standards in Hematology guidelines. Perhaps the final
word on antigen matching is yet to come from the
NHLBI working group studying transfusion-induced
alloimmunization.21
The data of Dajak and colleagues16 clearly illustrate
the detriment of not providing RhIG prophylaxis at 26 to
28 weeks’ gestation. Such antenatal administration of
RhIG reduced the rate of anti-D alloimmunization by
pregnancy to 0.18%, down from 1.8% when given only
after delivery.4,5 Unfortunately, RhIG is not available
worldwide in sufficient quantities or is deemed too costly
to provide universal antenatal prophylaxis.
Should the guidelines1 be changed with respect to the
frequency and timing of tests for unexpected antibodies
during pregnancy? The answer is a definite no. While there
could be stronger wording for testing D– women at 26 to
28 weeks’ gestation before antenatal RhIG, and for third-
trimester screening of D– women who have received
blood transfusions, the absence of cases in which in utero
death could have been prevented by medical intervention
before delivery does not support significant changes to
the current guidelines.
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